ArticleJournal of glaucoma2025
Longitudinal Trends in Resource Utilization Associated With Newly Diagnosed Primary Angle Closure Glaucoma in the United States.
Article in Journal of glaucoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
PRÉCIS: The average cumulative 2-year cost following first primary angle closure glaucoma diagnosis was $2960. Elderly and Black patients were at higher risk of being among the costliest 5% (>$9813) of cases, accounting for 21.3% of costs. PURPOSE: To assess longitudinal eye care costs associated with newly diagnosed primary angle closure glaucoma (PACG) in the United States.
methodsPatients with a diagnosis of PACG between 2009 and 2017 were identified in Optum's deidentified Clinformatics Data Mart Database based on International Classification of Diseases (ICD) codes. Newly diagnosed PACG was defined as: (1) diagnosis by an ophthalmologist or optometrist; (2) observable for at least 12 months before and 24 months after index diagnosis; (3) no prior history of glaucoma treatment; (4) PACG-related treatment initiated after index diagnosis. Logistic regression modeling was performed to identify risk factors for being in the top 5% of cumulative 2-year costs.
resultsAmong 12,673 eligible patients, the average cumulative 2-year cost following first PACG diagnosis was $2960. Patient costs were highest in the 6 months immediately following diagnosis, accounting for 52.3% of all 2-year costs. 56.7% of all 2-year costs were related to treatment procedures. The costliest 5% (>$9813) of patients accounted for 21.3% of all 2-year PACG-related costs. Risk factors for being in the costliest 5% ( P <0.05) included older age, Black race, PPO or other Medicare insurance product, living in the Midwest or the South, and recent diagnosis of anatomic narrow angles (ANA).
conclusionCosts associated with newly diagnosed PACG were found to be disproportionately driven by a small subset of cases. Elderly and Black patients were more likely to be within the top 5% of cumulative 2-year costs. Identifying and preventing the costliest PACG cases could reduce PACG-related eye care expenditures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.